Rodríguez BI, Ginarte VM, Peteiro C, Toribio J

Idioma: Español
Referencias bibliográficas: 26
Paginas: 136-140
Archivo PDF: 234.50 Kb.

RESUMEN

Los inhibidores del EGF-R son una familia de fármacos antineoplásicos que se están utilizando como tratamiento de distintos tumores sólidos. Su empleo se ha asociado a la aparición de efectos secundarios dermatológicos, fundamentalmente erupciones de lesiones pustulosas y pápulo-pustulosas foliculares, monomorfas en cara y tronco. Presentamos cuatro pacientes que desarrollaron una erupción acneiforme en cabeza y tronco, días después del inicio del tratamiento. Destacamos, por tanto, la creciente frecuencia de efectos secundarios cutáneos que están apareciendo con las nuevas terapias emergentes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1.Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-31.

2. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60:15-23.

3. 3.Baselga J, Averbuch SD. ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000;60:33-40.

4. 4.Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984;83:385-93.

5. Philpott MP, Kealey T. Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles. J Invest Dermatol 1994;102:186-91.

6. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (‘Iressa’), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.

7. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (‘Iressa’), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.

8. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ. Evaluation of safety and efficacy of gefitinib (‘Iressa’, zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer (revista electrónica) 2004;4:51.

9. 9.Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (‘Iressa’), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147: 598-601.

10. 10.Fernández-Galar M, España A, López-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004;29:138-40.

11. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-6.

12. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238-41.

13. 13.Trojan A, Jacky E, Follath F, Dummer R. Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition. Swiss Med Wkly 2003;133:22-3.

14. 14.Walon L, Gilbeau C, Lachapelle JM. Éruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereol 2003;130:443-6.

15. 15.Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.

16. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaró JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.

17. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006;94:85-92.

18. 18.Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003;9:2389-90.

19. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.

20. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.

21. 21.Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17(11 Supl. 12):23-8.

22. 22.Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.

23. 23.Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.

24. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.

25. 25.Pérez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46.

26. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849-51.